COMPANY PROFILE

Neogene Therapeutics

Developing technologies to enable the engineering of T cells with neo-antigen specificities that will display an optimized ability to seek and destroy cancer cells

Amsterdam, NetherlandsFounded 2018Biotech & Life Sciences

Valuation $250–500M Last recorded · 2022

Headcount <100 Current team size

Total funding $100–500M Disclosed equity funding

Unlock exact values

About Neogene Therapeutics

Neogene Therapeutics is at the forefront of cancer treatment innovation, specializing in the development of fully personalized T cell therapies. The company operates in the biotechnology and healthcare sectors, targeting patients with various forms of cancer. Neogene's business model revolves around cutting-edge research and development, focusing on creating tailored therapies that harness the body's immune system to fight cancer. Revenue is generated through partnerships, grants, and potentially future sales of their proprietary therapies. The company serves a global market, with operations based in Amsterdam and New York, aiming to provide groundbreaking solutions for cancer patients worldwide.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2018
Headquarters: Amsterdam, Netherlands
Employees: 48
Open positions: None listed
Dealroom signal: 61.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Nov 2022	$320M	$320M	AstraZeneca	↗
SERIES AOther financing	Sep 2020	$110M	$440M	Polaris Partners · Pontifax Funds · Vida Ventures · EcoR1 Capital	—

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Neogene Therapeutics website traffic

Latest recorded traffic for Neogene Therapeutics is 1.4K monthly website visits, down 39.1% over the last three months. Neogene Therapeutics's team declined 51% over the past year.

Latest monthly visits1.4K 3-month web change-39.1% 1-year team growth-51%

Monthly website visitsMar 2020–Jun 2025

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ATAscidian TherapeuticsEnables precise post-transcriptional editing of genes, resulting in full-length, functional proteins at the right levels, in the right cells, at the right time	Boston, United States	Operational	47	$90M	$250M
ATAtalanta TherapeuticsPioneering RNAi treatments for neurodegenerative diseases	Boston, United States	Operational
CTCartesian TherapeuticsCartesian \| Developing potent, safer cell and gene therapies for cancer and autoimmune diseases - Cartesian	Gaithersburg, United States	Operational
FEFemtogenixDNA-interactive payloads for antibody-drug conjugates	St Albans, United Kingdom	Operational
ETEpics TherapeuticsDrug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic mechanisms involved in cancer development	Charleroi, Belgium	Operational
LOLocanaCreating a new class of gene therapies by targeting disease-causing messenger RNA	San Diego, United States	Operational
TBTILT BiotherapeuticsTILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments	Helsinki, Finland	Operational
THTheraBiologicsA proprietary human nsc platform for cancer treatment	United States	Operational